1. Copy-number variants in clinical genome sequencing: deployment and interpretation for rare and undiagnosed disease.
- Author
-
Gross AM, Ajay SS, Rajan V, Brown C, Bluske K, Burns NJ, Chawla A, Coffey AJ, Malhotra A, Scocchia A, Thorpe E, Dzidic N, Hovanes K, Sahoo T, Dolzhenko E, Lajoie B, Khouzam A, Chowdhury S, Belmont J, Roller E, Ivakhno S, Tanner S, McEachern J, Hambuch T, Eberle M, Hagelstrom RT, Bentley DR, Perry DL, and Taft RJ
- Subjects
- Adolescent, Child, Child, Preschool, Chromosome Mapping methods, Cohort Studies, Female, Genetic Testing methods, Genome, Human, Genomics methods, Humans, Infant, Male, Rare Diseases diagnosis, Undiagnosed Diseases diagnosis, Whole Genome Sequencing methods, Young Adult, DNA Copy Number Variations genetics, Rare Diseases genetics, Undiagnosed Diseases genetics
- Abstract
Purpose: Current diagnostic testing for genetic disorders involves serial use of specialized assays spanning multiple technologies. In principle, genome sequencing (GS) can detect all genomic pathogenic variant types on a single platform. Here we evaluate copy-number variant (CNV) calling as part of a clinically accredited GS test., Methods: We performed analytical validation of CNV calling on 17 reference samples, compared the sensitivity of GS-based variants with those from a clinical microarray, and set a bound on precision using orthogonal technologies. We developed a protocol for family-based analysis of GS-based CNV calls, and deployed this across a clinical cohort of 79 rare and undiagnosed cases., Results: We found that CNV calls from GS are at least as sensitive as those from microarrays, while only creating a modest increase in the number of variants interpreted (~10 CNVs per case). We identified clinically significant CNVs in 15% of the first 79 cases analyzed, all of which were confirmed by an orthogonal approach. The pipeline also enabled discovery of a uniparental disomy (UPD) and a 50% mosaic trisomy 14. Directed analysis of select CNVs enabled breakpoint level resolution of genomic rearrangements and phasing of de novo CNVs., Conclusion: Robust identification of CNVs by GS is possible within a clinical testing environment.
- Published
- 2019
- Full Text
- View/download PDF